Class action lawsuits
Alto Neuroscience, Inc. (NYSE: ANRO) faces a securities lawsuit after investors claimed the company made false statements about its product pipeline, ALTO-100. The lawsuit alleges that the company's product was less effective in treating major depressive disorder than investors were led to believe. As a result, investors may
Class action lawsuits
Investors who purchased shares of Alto Neuroscience, Inc. during a specific timeframe have been issued a notice to potentially recover losses due to alleged false and misleading statements made by the company. The Gross Law Firm is leading the class action lawsuit against Alto Neuroscience, Inc. (NYSE: ANRO), claiming that
Class action lawsuits
The Rosen Law Firm has filed a class action lawsuit against XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP (NYSE: XIFR) (NYSE: NEP) on behalf of purchasers of common units during the period from September 27, 2023, to January 27, 2025. The lawsuit alleges that the company'
Class action lawsuits
A class action lawsuit has been filed against Neogen Corporation (NASDAQ: NEOG) on behalf of investors who purchased the company's common stock between January 5, 2023, and June 3, 2025. The lawsuit alleges that Neogen made false and/or misleading statements about the integration of the company, leading
Class action lawsuits
Purchasers of Lineage, Inc. common stock following its initial public offering in July 2024 may be entitled to compensation due to a class action lawsuit filed against the company. The lawsuit claims that Lineage's registration statement was false and misleading, failing to disclose sustained weakening in customer demand,
Class action lawsuits
Georgia parents are being forced to pay exorbitant foster care fees, with some facing nearly $500 a month in costs, despite being impoverished and unable to afford the payments. The fees, imposed by the Georgia Department of Human Services, are being challenged in a lawsuit filed by a civil rights
Class action lawsuits
The Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023, and June 24, 2025, of the important August 25, 2025, lead plaintiff deadline. The lawsuit alleges that Sarepta made false and misleading statements about its prescription
Class action lawsuits
A class action lawsuit has been filed against Altimmune, a clinical-stage biopharmaceutical company, following the company's announcement of disappointing results from its IMPACT Phase 2b trial of Pemvidutide for the treatment of MASH. The trial's primary endpoint, fibrosis reduction, failed to achieve statistical significance, leading to
Class action lawsuits
Investors who purchased common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025, and June 23, 2025, may be entitled to compensation due to alleged false and misleading statements made by the company's defendants. A class action lawsuit has been filed, and investors have
Class action lawsuits
Investors who purchased Novo Nordisk securities between May 7, 2025, and July 28, 2025, may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. A class action lawsuit has been filed against Novo Nordisk A/S (NYSE: NVO) due to allegedly misleading
Class action lawsuits
Pomerantz LLP has announced a class action lawsuit against Hims & Hers Health, Inc. (HIMS) regarding securities fraud and unlawful business practices. The lawsuit concerns allegations that Hims & Hers and its officers or directors have engaged in deceptive promotion and sales of counterfeit versions of the FDA-approved medication Wegovy.
Class action lawsuits
Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024, and July 21, 2025, both dates inclusive, of the important September 22, 2025, lead plaintiff deadline in the securities class action first filed by the Firm. The
